The results in Fig. 5A, C show that intravenous injection of CCL22 into KYSE410 and KYSE510 xenografts increased the tumor size (Fig. 5A) and enhanced the activation of AKT (Fig. 5B) and the expression of Ki67, CD31, and LYVE-1 (Fig. 5C), as evaluated by quantitative ELISAs. The gene discussed is CCL22; the disease is neoplasm.